Anti-VEGF AAV2 injections: The fewer the better

Sci Transl Med. 2017 Jun 7;9(393):eaan4921. doi: 10.1126/scitranslmed.aan4921.

Author

Affiliation

¹ Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213, USA. Email: lbyrne@pitt.edu.

PMID: 28592565
DOI: 10.1126/scitranslmed.aan4921

Abstract

A single intravitreal injection of AAV2 provides sustained delivery of anti-VEGF protein for the treatment of neovascular AMD.

Copyright © 2017, American Association for the Advancement of Science.

Publication types

Comment

MeSH terms

Angiogenesis Inhibitors
Bevacizumab
Humans
Intravitreal Injections
Vascular Endothelial Growth Factor A*
Visual Acuity
Wet Macular Degeneration*

Substances

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Bevacizumab